Please login to the form below
medicines access
This page shows the latest medicines access news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca's rare disease unit receives NICE recommendation for Wolman disease therapy in infants
The therapy will now be fast-tracked via NHS England’s Innovative Medicines Fund to enable routine patient access up to five months earlier than would otherwise be the case.
Latest news
-
Landmark UK medicines deal to save NHS £14bn in medicine costs
The Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) will provide patients with the latest lifesaving treatments and boost the UK’s global position in advanced healthcare, technology and ... The mechanism income will support
-
Alliance for mRNA Medicines launched to accelerate global innovation
A group of 31 biotechnology, biopharma and life sciences companies and educational institutions have launched the first global organisation dedicated to advancing mRNA medicines. ... This is a pivotal moment for mRNA medicines," said Andy Geall, chairman
-
Novartis’ Cosentyx receives FDA approval for hidradenitis suppurativa
Novartis said it has an agreement with NHS England to enable eligible HS patients to obtain immediate access to Cosentyx through the interim Innovative Medicines Fund, which provides funding to accelerate ... Additionally, the New Treatment Fund in Wales,
-
Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa
Novartis said it has an agreement with NHS England to enable eligible HS patients to obtain immediate access to Cosentyx through the interim Innovative Medicines Fund, which provides funding to accelerate ... Additionally, the New Treatment Fund in Wales,
-
Life sciences leaders warn against ‘unworkable’ changes to UK medicines scheme
The scheme could impact UK life sciences and NHS patient access to medicines. ... The pharmaceutical industry believes that the changes to the medicines scheme are ‘unworkable’ and could be highly damaging to UK life sciences and NHS patient access
More from news
Approximately 4 fully matching, plus 486 partially matching documents found.
Latest Intelligence
-
Focusing in on real-world evidence and its capabilities
Using real-world data pharmacy and medical claims, the safety profile for this treatment in males was shown to be consistent with that in females, increasing access to treatments for a ... clinical trials is challenging – if not impossible – and
-
Can the patient pathway provide a route to success?
Stage 3 – initial treatment and coordinated care: ‘Act4Biosimilars’ initiative. While biosimilars provide more affordable alternatives to biologics, access inequities are preventing many patients from benefiting from them. ... An initiative by
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
The biggest gaps are often found in disadvantaged populations with the least timely access to cancer care. ... An IHE report published by the European Society for Medical Oncology in 2020 highlighted wide disparities in access to new cancer medicines,
-
Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease
Bayer is partnering with clinicians, policymakers and patient groups to accelerate diagnoses, address unmet needs, improve integrated healthcare solutions and support the sector with a portfolio of innovative medicines – at the ... We must be bold to
-
Why pharma needs to ‘walk the talk’ on improving the greener patient journey
of medicines as well as their clinical outcomes in approval and reimbursement processes. ... that may restrict access to medicines on non-clinical grounds.
More from intelligence
Approximately 0 fully matching, plus 116 partially matching documents found.
Latest appointments
-
VMLY&Rx launches new payer agency in the US
The VMLY&Rx Payer team will aim to provide strategic support to clients in the US working across the product lifecycle, including the delivery of patient-centred, value-focused access and ... They play a huge role in determining whether patients can
-
Pfizer’s Alan Maine moves to Edelman
Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area ... During his time at Pfizer, Maine also
-
Sobi names Holly May VP of sales and marketing, US
May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country. ... She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate
-
Inceptua Medicines Access appoints senior new-hires
Multipharma’s new speciality business unit, Inceptua has appointed Ruth Rostron as its new senior project manager, a role that will see her focus on design and implementation of medicines access
-
Sandoz UK promotes Tim de Gavre to country head
As a company, Sandoz has an exciting portfolio of medicines and future product pipeline. ... I look forward to working with the Sandoz team, and in partnership with the NHS to help patients access these important medicines.”.
More from appointments
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest from PMHub
-
So, what is happening with specialised commissioning in the NHS?
Join Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) and David Thorne (Principal Associate, Mtech Access) for our live webinar on Friday 8. ... Join David Thorne (Principal Associate, Mtech Access) in his interview of Malcolm
-
The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of innovative ... Choosing the right pricing and payment
-
VPAS: The importance of making the right arguments, even in challenging times
The environment to argue for a more generous settlement for industry, through the controversial voluntary scheme for branded medicines pricing and access ( VPAS), could not be tougher. ... fairer and more reasonable clawback rate are centred around
-
Accession reaches milestone for digital innovation in market access
and one that perfectly demonstrates why we at Accession are all so passionate about the power of market access to ensure patients gain access to life changing medicines’. ... Founded in 2011, Accession delivers value, access and technology services to
-
A new prescription for the U.S. healthcare market?
The U.S. is by far the most profitable market for pharmaceutical companies – in 2021, the country spent $574 billion on medicines. ... There is no doubt that health reform is required, to adapt to the changing economic environment, cost containment
More from PMHub
Approximately 0 fully matching, plus 31 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
